- All Courts
- Federal Courts
- Bankruptcies
- PTAB
- ITC
Filters
Like full text docket searches?
Get docket alerts, perform legal research, get updates of major decisions and orders, use our advanced analytics, and more. To schedule a demo, contact us at sales@docketalarm.com or create your account.
Date Filed
Dollars
Find cases based on dollar amount with searches like:
$100k-$10M.
Read the details here.
Displaying 9-23 of
155 results
12 Other Refund request: Petitioners Request for Refund of Post Institution Fees
Document
IPR2025-01139, No. 12 Other Refund request - Petitioners Request for Refund of Post Institution Fees (P.T.A.B. Jan. 6, 2026)
|
|
Cite Document
7 POPR filed: Patent Owner Preliminary Response
Document
IPR2025-01139, No. 7 POPR filed - Patent Owner Preliminary Response (P.T.A.B. Oct. 1, 2025)
|
|
Cite Document
8 Notice Updated Mandatory Notice: Petitioners Updated Mandatory Notices
Document
IPR2025-01139, No. 8 Notice Updated Mandatory Notice - Petitioners Updated Mandatory Notices (P.T.A.B. Oct. 1, 2025)
|
|
Cite Document
4 Notice Mandatory Notice: Patent Owners Mandatory Notice
Document
IPR2025-01139, No. 4 Notice Mandatory Notice - Patent Owners Mandatory Notice (P.T.A.B. Jun. 27, 2025)
|
|
Cite Document
3 Notice Power of Attorney: Patent Owner Actelion Pharmaceuticals Ltds Power of ...
Document
IPR2025-01139, No. 3 Notice Power of Attorney - Patent Owner Actelion Pharmaceuticals Ltds Power of Attorney (P.T.A.B. Jun. 27, 2025)
|
|
Cite Document
2 Notice Power of Attorney: Notice Power of Attorney
Document
IPR2025-01139, No. 2 Notice Power of Attorney - Notice Power of Attorney (P.T.A.B. Jun. 10, 2025)
|
|
Cite Document
1 Petition as filed: Petition as filed
Document
IPR2025-01139, No. 1 Petition as filed - Petition as filed (P.T.A.B. Jun. 10, 2025)
|
|
Cite Document
2021 Exhibit: Packer, M et al, Double Blind, Placebo Controlled Study of the Efficac...
Document
IPR2025-01139, No. 2021 Exhibit - Packer, M et al, Double Blind, Placebo Controlled Study of the Efficacy of Flosequinan in Patients With Chronic Heart Failure (P.T.A.B. Oct. 1, 2025)
|
|
Cite Document
2018 Exhibit: Adcirca® Label
Document
IPR2025-01139, No. 2018 Exhibit - Adcirca® Label (P.T.A.B. Oct. 1, 2025)
|
|
Cite Document
2023 Exhibit: Stassi, DL et al, Ethyl substituted erythromycin derivatives produced ...
Document
IPR2025-01139, No. 2023 Exhibit - Stassi, DL et al, Ethyl substituted erythromycin derivatives produced by directed metabolic engineering (P.T.A.B. Oct. 1, 2025)
|
|
Cite Document
1051 Exhibit: EX 1051 Complaint 125 cv 15227 RMB SAK
Document
IPR2025-01139, No. 1051 Exhibit - EX 1051 Complaint 125 cv 15227 RMB SAK (P.T.A.B. Oct. 1, 2025)
|
|
Cite Document
2028 Exhibit: Humbert, M et al, Combination of bosentan with epoprostenol in pulm...
Document
IPR2025-01139, No. 2028 Exhibit - Humbert, M et al, Combination of bosentan with epoprostenol in pulmonary arterial hypertension BREATHE 2 (P.T.A.B. Oct. 1, 2025)
|
|
Cite Document
2024 Exhibit: Humbert, M et al, Treatment of Pulmonary Arterial Hypertension
Document
IPR2025-01139, No. 2024 Exhibit - Humbert, M et al, Treatment of Pulmonary Arterial Hypertension (P.T.A.B. Oct. 1, 2025)
|
|
Cite Document
2022 Exhibit: Resnick, MS et al, Flosequinan, a vasodilator with a novel mechanism...
Document
IPR2025-01139, No. 2022 Exhibit - Resnick, MS et al, Flosequinan, a vasodilator with a novel mechanism of action, (P.T.A.B. Oct. 1, 2025)
|
|
Cite Document
1051 Exhibit: EX 1051 Complaint 125 cv 15227 RMB SAK
Document
IPR2025-01139, No. 1051 Exhibit - EX 1051 Complaint 125 cv 15227 RMB SAK (P.T.A.B. Oct. 1, 2025)
|
|
Cite Document
